Possible Link Between Pembrolizumab Cutaneous Adverse Reaction, Progression-Free Survival

Share this content:
Cutaneous adverse events while receiving pembrolizumab has been linked with better treatment response, especially in melanoma.
Cutaneous adverse events while receiving pembrolizumab has been linked with better treatment response, especially in melanoma.

Development of cutaneous adverse events while receiving pembrolizumab has been linked with better treatment response, especially in patients with melanoma, suggested a study published online in JAMA Dermatology.

Pembrolizumab, an immunomodulatory anti-programmed death-1 drug is associated with cutaneous adverse events. In this single-institution, retrospective medical record review, 83 patients who were enrolled in two clinical trials and received at least one dose of pembrolizumab were included.

Patients were grouped into the following regimens: 43 patients received 10 mg/kg every 3 weeks, 24 patients received 10 mg/kg every 2 weeks, 16 patients received 2 mg/kg every 3 weeks.

A total of 66 patients were treated for melanoma, 15 patients were treated for lung cancer, one patient for prostate cancer, and one patient for Merkel cell carcinoma. Patients were evaluated for occurrence, severity, type of cutaneous adverse event, as well as treatment response.

RELATED: Veliparib Plus Temozolomide for Melanoma Improves Progression-Free Survival

Nearly half (42%) of all patients developed cutaneous adverse events. The most common were macular papular eruption (24 [29%]), pruritus (10 [12%]), and hypopigmentation (7 [8%]). All patients who experienced hypopigmentation were being treated for melanoma.

Survival analysis revealed that patients with cutaneous adverse events had significantly longer progression-free intervals in all groups compared with patients who did not.

Reference

  1. Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Derm. 2015. [epub ahead of print]. doi: 10.1001/jamadermatol.2015.1916.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters